Cargando…
Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.
Decarbazine is an imidazole dimethyltriazene with reproducible activity in patients with metastatic melanoma. CB10-277 is a phenyl dimethyltriazene which, like dacarbazine, requires metabolic activation to its corresponding monomethyl species for antitumour activity. In preclinical models (human mel...
Autores principales: | Foster, B. J., Newell, D. R., Carmichael, J., Harris, A. L., Gumbrell, L. A., Jones, M., Goodard, P. M., Calvert, A. H. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968184/ https://www.ncbi.nlm.nih.gov/pubmed/8431367 |
Ejemplares similares
-
Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion.
por: Foster, B. J., et al.
Publicado: (1993) -
A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma.
por: Bleehen, N. M., et al.
Publicado: (1994) -
The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice.
por: Jodrell, D. I., et al.
Publicado: (1991) -
Health Tract, No. 277: The Tomatoe
Publicado: (1867) -
Preclinical pharmacokinetics of benznidazole.
por: Workman, P., et al.
Publicado: (1984)